Literature DB >> 2723032

Functional capacity of immunoglobulin G preparations and the F(ab')2 split product.

R W Steele1, R W Steele1.   

Abstract

Five immunoglobulin G preparations, including one 5S F(ab')2 split product, were compared for activity against common bacterial, viral, and protozoan pathogens. Standard assays were used to quantitate antibodies to tetanus, diphtheria, cytomegalovirus, herpes simplex virus types 1 and 2, rubella virus, and Toxoplasma gondii. Opsonization and killing of bacteria were examined by chemiluminescence methods using Streptococcus pneumoniae types 5, 12F, and 14 and Staphylococcus aureus. Antibodies to the viral pathogens and T. gondii were not detectable for the 5S immunoglobulin even at high concentrations (50 mg/ml) but were present in all 7S preparations at immunoglobulin concentrations of 10 mg/ml. Relatively lower activities for tetanus and diphtheria antibody were also seen with the F(ab')2 product. Opsonizing capacity against all pneumococcal serotypes and Staphylococcus aureus was lowest for the 5S product and highest for the commercially available intravenous immunoglobulin product that is purified by using a pH 4.25 formulation. These data do not support potential clinical usefulness of immunoglobulin G split products and suggest wide variations of specific antibody among commercial intravenous immunoglobulin preparations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2723032      PMCID: PMC267388          DOI: 10.1128/jcm.27.4.640-643.1989

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

1.  Evaluation of serum opsonic capacity by quantitating the initial chemiluminescent response from phagocytizing polymorphonuclear leukocytes.

Authors:  R C Allen
Journal:  Infect Immun       Date:  1977-03       Impact factor: 3.441

2.  The biological properties of immunoglobulin G and its split products [F(ab')2 and Fab].

Authors:  H H Sedlacek; P Gronski; T Hofstaetter; E J Kanzy; H U Schorlemmer; F R Seiler
Journal:  Klin Wochenschr       Date:  1983-08-01

3.  [Protective action of undegraded and S-sulfonated 7S antibodies in 4 different experimental virus infections].

Authors:  R Johannsen; E J Kanzy; O Ackerman; R Barth; H J Bengelsdorff; J Hinz; E Weinmann; H Gruschkau; F R Seiler
Journal:  Beitr Infusionther Klin Ernahr       Date:  1982

4.  Two nephelometric methods compared with a radial immunodiffusion method for the measurement of IgG, IgA and IgM.

Authors:  G C Blanchard; R Gardner
Journal:  Clin Biochem       Date:  1980-04       Impact factor: 3.281

5.  Reversal of inotropic effects of digoxin by specific antibodies and their Fab fragments in the conscious dog.

Authors:  H R Ochs; S F Vatner; T W Smith
Journal:  J Pharmacol Exp Ther       Date:  1978-10       Impact factor: 4.030

6.  In vitro and in vivo activities of different immunoglobulin G preparations from the rabbit against Enterobacteriaceae.

Authors:  M Trautmann; Y Müller-Leutloff; T Hofstaetter; F R Seiler; H Hahn
Journal:  Vox Sang       Date:  1985       Impact factor: 2.144

7.  The requirement for the Fc portion of antibody in antigen-antibody complex-mediated suppression.

Authors:  E L Morgan; C H Tempelis
Journal:  J Immunol       Date:  1978-05       Impact factor: 5.422

8.  Efficacy of modified human immune serum globulin in the treatment of experimental murine infections with seven immunotypes of Pseudomonas aeruginosa.

Authors:  S D Davis
Journal:  J Infect Dis       Date:  1975-06       Impact factor: 5.226

9.  In-vivo phagocytosis: enhancement of bacterial clearance by native and enzyme-treated immunoglobulins.

Authors:  W Ax; E J Kanzy; F R Seiler
Journal:  Immunobiology       Date:  1981       Impact factor: 3.144

10.  The adsorption of proteins on erythrocytes treated with tannic acid and subsequent hemagglutination by antiprotein sera.

Authors:  S V BOYDEN
Journal:  J Exp Med       Date:  1951-02       Impact factor: 14.307

View more
  1 in total

Review 1.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.